NCT02810054

Brief Summary

After performing the power calculation, healthy adult participants for the study will be randomly allocated into two groups. The intervention group will receive minimally invasive surgical techniques (MIST) with enamel matrix derivative (Emdogain) as a treatment of intrabony periodontal defect. The control group will receive minimally invasive surgical techniques (MIST) without enamel matrix derivative (Emdogain). Clinical attachment level (CAL) gain and periodontal pocket depth (PPD) reduction as well as the position of gingival margin (REC) as the main outcomes and the radiographic intrabony infill, bleeding on probing (BoP), full mouth plaque score (FMPS) and full mouth bleeding score (FMBS) as secondary outcome will be recorded for the participants by 3 examiners at three stages:

  1. 1.Before the procedure as a baseline record.
  2. 2.6 months after surgery, all parameters EXCEPT intra oral periapical (PA) radiographs.
  3. 3.12 months after surgery.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2016

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 20, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 22, 2016

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2016

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2018

Completed
Last Updated

June 28, 2016

Status Verified

June 1, 2016

Enrollment Period

1.8 years

First QC Date

June 20, 2016

Last Update Submit

June 27, 2016

Conditions

Keywords

regenerationintrabony defectsenamel matrix derivativeMIST

Outcome Measures

Primary Outcomes (1)

  • clinical attachment level gain CAL

    periodontal clinical attachment level gain

    12 months

Secondary Outcomes (5)

  • radiographic bone fill

    12 months

  • full mouth bleeding score FMBS

    12 months

  • full mouth dental plaque score FMPS

    12 months

  • periodontal probing depth reduction PPD

    12 months

  • marginal gingival recession REC

    12 months

Study Arms (2)

Control Group (MIST without EMD)

SHAM COMPARATOR

Those participants who will receive the minimally invasive surgical techniques but without application Enamel Matrix Derivative (EMD) .

Procedure: Minimally Invasive Surgical Techniques (MIST)

Test Group (MIST with EMD)

EXPERIMENTAL

Those participant who will receive the minimally invasive surgical techniques with the application of Enamel Matrix Derivative (EMD) .

Procedure: Minimally Invasive Surgical Techniques (MIST)Procedure: Enamel Matrix Derivative (EMD)

Interventions

Using minimally invasive surgical techniques.

Control Group (MIST without EMD)Test Group (MIST with EMD)

Use of enamel matrix derivative for the treatment of intrabony periodontal defects.

Test Group (MIST with EMD)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Candidate from both gender males and females with moderate to advanced periodontal disease.
  • years old and more.
  • Probing pocket depth (PPD) of \> 5mm and clinical attachment loss (CAL) of \>6mm.
  • and 3-wall angular intra bony periodontal defects.
  • Full-mouth plaque score (FMPS) of \< 20%.
  • Full-mouth bleeding score (FMBS) of \< 15%.
  • Medically fit and healthy.
  • Not allergic to any materials or medications that could be used during or after the procedure.

You may not qualify if:

  • Patients with diabetes and any haematological disorders that might compromise the procedure.
  • wall and crater defects.
  • Immunocompromised patients and those with known allergy to one of the materials or medications to be used.
  • Patients whose FMPS \> 20%.
  • Smokers.
  • Pregnant women.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Kevin G Seymour

    The University of Manchester

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

June 20, 2016

First Posted

June 22, 2016

Study Start

September 1, 2016

Primary Completion

July 1, 2018

Study Completion

August 1, 2018

Last Updated

June 28, 2016

Record last verified: 2016-06

Data Sharing

IPD Sharing
Will not share

Individual Participant data will not be shared however once anonymised the results may be published.